NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
A New Era in Hemophilia A Prophylaxis: Dr. Shima Presented Groundbreaking Phase I/II Results for NXT007
Jun 23, 2025, 12:40

A New Era in Hemophilia A Prophylaxis: Dr. Shima Presented Groundbreaking Phase I/II Results for NXT007

NXT007 Hemophilia A Prophylaxis took center stage today when Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post  on X.

“A New Era in Haemophilia A Prophylaxis. Dr. Shima presented groundbreaking phase I/II results for NXT007, a next-generation bispecific antibody: 30 patients with severe haemophilia A (no inhibitors), age range: 12-65 years (median age 39.5 years), subcutaneous dosing: 0.072-1.08 mg/kg every 4 weeks.
Higher dose cohorts (B-3, B-4) achieved FVIII-equivalent activity in the normal range.
Well-tolerated profile with no thromboembolic events, but high anti-drug antibody prevalence: 22/30 patients (73%) and effect on plasma concentrations in 2/22.”

Hemophilia A

Stay up to date with Hemostasis Today

Hematology Hemophilia Hemostasis Today Prophylaxis Wolfgang Miesbach
NewsFeed